Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward ...

Stocks in the Nordic region declined Tuesday, with the OMX Nordic 40 Index declining 2.2%. Genmab A/S posted the largest decline among large stocks during the session, declining 9.2%, followed by ...

RBC Capital analyst Alistair Campbell lowered the firm’s price target on Genmab (GMAB) to DKK 2,300 from DKK 2,400 and keeps an Outperform ...

Genmab (GMAB) announced that Johnson & Johnson (JNJ) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38. “While the ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on Genmab (GMAB) to $45 from $50 but keeps a Buy rating on the shares.

Danish cancer specialist Genmab’s stock took a hit after US healthcare giant Johnson & Johnson opted not to license its ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, ...

Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...